Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dorgenmeltucel-L + nivolumab
- Development stage
- Unknown
- Lead developer
- Lumos Pharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intravenous
01
Overview
**dorgenmeltucel-L + nivolumab** is a combination immunotherapy regimen under clinical investigation, primarily for the treatment of advanced melanoma. Dorgenmeltucel-L (also called HyperAcute Melanoma or HAM) is a whole-cell allogeneic melanoma vaccine that expresses the αGal epitope, stimulating a hyperacute immune response and epitope spreading against tumor-associated antigens. Nivolumab is a monoclonal antibody targeting the immune checkpoint protein PD-1, acting as a checkpoint inhibitor to restore T-cell activity against cancer. This combination aims to synergistically provoke and sustain anti-tumor immunity beyond what each agent achieves separately[2].
- Other names
- HAMdorgenmeltucel-Lnivolumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)α-Gal (Alpha-gal epitope)
Beyond the preview
Go deeper on dorgenmeltucel-L + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dorgenmeltucel-L + nivolumab.